BiomX Inc.
American Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.- Similar Companies
- Business
- BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Company News
BiomX Inc. (PHGE) Q3 2024 Earnings Call Transcript
BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates
BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024
BiomX Announces a Mandatory Unit Separation
BiomX Stock Gains From Favorable Study Data Presentation on BX004
BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference
BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference
UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split
BiomX Inc. (PHGE) Q2 2024 Earnings Call Transcript
BiomX Inc. Announces 1-for-10 Reverse Stock Split
BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates
BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024
BiomX Inc. Announces NYSE American Acceptance of Plan to Regain Listing Compliance
BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock
BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024
BiomX (PHGE) Q1 2024 Earnings Call Transcript
BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates
BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024
BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)